Cartesian reveals long-term mid-stage data for cell therapy in myasthenia gravis

Cartesian Therapeutics said its autologous CAR-T therapy has shown “sustained benefits” in people with a rare autoimmune disease according to the latest data cut from a Phase 2b trial. Four out of 12 evaluable patients ...